PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: UK PM faces battle over "un-British" vaccine passports

Wed, 07th Apr 2021 06:50

(Alliance News) - UK Prime Minister Boris Johnson faces a battle to introduce domestic vaccine passports after running into fierce opposition from Tory critics and Labour.

A government review into "Covid status certification" found they could "potentially play a role" in settings such as theatres, nightclubs and mass events, and might also be used in pubs and restaurants to reduce social distancing restrictions.

The prospect of having to show a certificate to access shops or bars has outraged members of the Covid Recovery Group of Conservatives, while Labour hit out at the "discriminatory" and "poorly thought-through" proposals.

The use of certificates – which would include vaccination status, test results or evidence of someone having contracted and recovered from Covid-19 – is opposed by at least 40 Conservative MPs.

With Labour's opposition also hardening, along with the SNP raising concerns, the government would face difficulties in getting the measures through the Commons if Johnson pushed them to a vote.

Ministers have ruled out bringing in certification for either the April 12 or May 17 stages of the road map but the documents – either in paper form or on an NHS app – could be introduced later this year.

Johnson suggested that vaccination passports for overseas travel were "going to be a fact of life" because a lot of countries were looking at the possibility.

On the domestic front, he indicated "we are also going to look at the role of a number of signals that you can give that you are not contagious", highlighting the role for mass testing.

"From Friday, everybody can get free lateral flow tests on the NHS and on the web, over the internet," he said.

"I think that will also be very, very valuable in giving people confidence to open up."

Tory former minister Steve Baker, the deputy chairman of the CRG, said the requirement to show documents would be "un-British".

The government's review suggested that if an official system is not introduced, firms would be able to ask customers for proof of Covid status in order to access their premises anyway.

But Baker said: "Whether the government imposes this, recommends it or simply stands back and allows it to happen, Covid status certification would be entirely un-British and our country and values would become unrecognisable."

He warned the country could be changed forever into the "miserable dystopia of Checkpoint Britain".

The interim findings of the government's review said public transport and essential shops or services would not require vaccine passports.

But that left open the prospect of non-essential retail outlets being forced to check on their customers.

Shadow health secretary Jonathan Ashworth told the BBC: "I'm not going to support a policy that, here in my Leicester constituency, if someone wants to go into Next or H&M, they have to produce a vaccination certificate on their phone, on an app.

"I think that's discriminatory."

A senior Labour source said: "On the basis of what we've seen and discussed with ministers, we oppose the government's plans for domestic vaccine passports.

"They appear poorly thought-through, will put added burdens on business and run the risk of becoming another expensive Whitehall project that gets outsourced to friends of Tory ministers."

The SNP's Westminster leader, Ian Blackford, said the ministers must address the "considerable issues" on "equity, ethics and privacy".

"The UK Government hasn't published any proposals yet, and the Tory position has been mired in confusion and contradiction. On the basis of the information available, there is not a proposition in front of us that SNP MPs could support," he said.

"While there might be a need to consider means to facilitate international travel, any such proposals must only be agreed in consultation with the devolved governments."

In other developments:

– The trial of the Oxford University and AstraZeneca PLC vaccine in children was paused while regulators investigate reports of a rare form of blood clot among adults, but the university stressed that no safety concerns have arisen from the trial itself.

– Secondary school and college pupils in England will need to continue wearing face masks in class when they return after Easter as a precautionary measure.

– The Valneva Covid-19 vaccine, which is set to be manufactured in the UK, produces a "strong immune response", Health Secretary Matt Hancock said following promising results in an early-stage phase one/two study involving 153 people.

– The prime minister suggested he was considering allowing travellers returning from low-risk countries to take cheap and fast lateral flow tests rather than the more expensive PCR alternative.

– All pupils across Scotland, except those who are shielding, will be back in the classroom full-time following the Easter holidays.

– A further 20 people were reported to have died within 28 days of testing positive for Covid-19 as of Tuesday, bringing the UK total by that measure to 126,882.

– Figures to April 5 showed 31.6 million have received a first dose of vaccine, a rise of 40,744 on the previous day, while 5.5 million have also been given a second jab, an increase of 64,590.

Meanwhile, the prime minister insisted he would not deviate from his road map out of lockdown despite warnings from scientific advisers that the plan could result in a third wave of coronavirus cases and deaths.

The Scientific Pandemic Influenza Group on Modelling, which advises the government, produced a paper dated March 31 suggesting later stages of the road map out of lockdown was "highly likely" to lead to increased hospital cases and deaths.

Speaking to reporters during a visit to an AstraZeneca plant in Macclesfield, Johnson said: "At the moment, as I look at all the data, I can't see any reason for us to deviate from the road map that we have set out, we are sticking to it."

Further relaxations of restrictions in England are pencilled in for May 17 and June 21.

Johnson has already confirmed April 12 will see the next step along the road map, with shops, pub beer gardens, gyms and hairdressers among premises allowed to reopen.

By David Hughes, PA Political Editor

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.